TREATMENT OF NECHODGKIN'S LYMPHOMA WITH LILOTOMAB AND 177Lu-LILOTOMAB WITH SATETHRAXETAN

• 1. 具有降低的ADCP的奥滨尤妥珠单抗和利妥昔单抗变体 [P] . 中国专利： CN108699156A . 2018-10-23
• 2. Bcl-2抑制剂与利妥昔单抗和/或苯达莫司汀或与CHOP联合的协同抗肿瘤作用 [P] . 中国专利： CN110772640A . 2020-02-11
• 3. treatment of non-hodgkin's lymphoma using lilotomab and 177lu-lilotomab satetraxetan [P] . BR112019004838A2 . 2019-06-04

  机译： 利洛妥单抗和177lu-利洛妥单抗沙丁胺醇治疗非霍奇金淋巴瘤

• 4. TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN. [P] . MX2019003029A . 2019-09-13

  机译： 利洛妥单抗和177LU-利洛妥单抗星替克沙坦治疗非霍奇金淋巴瘤。

• 5. Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan [P] . IL265387D0 . 2019-05-30

  机译： 利洛他单抗和177lu-利洛托单抗沙丁胺醇治疗非霍奇金淋巴瘤

• 1. Individualized Treatment and Palliative Care for A 90-Year-Old Patient with Primary Gastric Diffuse Large-B Cell Lymphoma: 4 Year Follow-up and Inspiration [J] . Yanjie Cao, Jingqi Duan, Lifang Liu, 中国医学科学杂志（英文版） . 2021,第001期
• 2. Chinese Society of Clinical Oncology(CSCO)diagnosis and treatment guidelines for malignant lymphoma 2021(English version) [J] . Jun Zhu, Jun Ma 中国癌症研究（英文版） . 2021,第003期
• 3. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate [J] . Johan Blakkisrud, Ayca L??ndalen, Jostein Dahle, The Journal of Nuclear Medicine . 2017,第1期
• 4. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan [J] . Johan Blakkisrud, Ayca L??ndalen, Anne C.T. Martinsen, The Journal of Nuclear Medicine . 2017,第1期
• 5. Cell Cycle Kinase Inhibitors Potentiate the Effect of (177)lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines [J] . Rodland Gro Elise, Melhus Katrine, Dahle Jostein, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期
• 6. Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma [C] . Joana Dias, Solange Gil, Belmira Carrapico, PEGS . 2015
• 7. Understanding Racial and Ethnic Differences in Lymphoma Treatment and Outcomes in the United States [D] . Vaughn, John Leslie. 2021
• 8. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients [O] . Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, -1
• 9. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients [O] . Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, 2018

• 1. Diagnosis and treatment of pediatric anaplastic lymphoma kinasepositive large B-cell lymphoma:A case report [J] . Meng Zhang ,Ling Jin ,Yan-Long Duan . 世界临床病例杂志 . 2021,第017期
• 2. Secondary peripheral T-cell lymphoma and acute myeloid leukemia after Burkitt lymphoma treatment:A case report [J] . Li Huang ,Can Meng ,Dan Liu . 世界临床病例杂志 . 2021,第024期
• 3. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non- Hodgkin lymphoma: A case report [J] . Zhi-Yun Niu ,Li Sun ,Shu-Peng Wen . 世界临床病例杂志 . 2021,第010期
• 4. 利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤疗效与安全性的Meta分析 [C] . PENG Xiao-juan ,彭小娟 . 中华中医药学会血液病分会第三次学术年会、中国民族医药学会血液病分会2017年学术年会 . 2017
• 5. 利妥昔单抗联合来那度胺治疗B细胞非霍奇金淋巴瘤疗效及安全性分析 [A] . 赵冉 . 2021